jobs

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by PureTech Health plc

< Previous 1 2 3 4 Next >
PureTech Provides End of Year Report on Key Progress
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech’s LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and GABAA Receptor Target Engagement in Healthy Volunteers
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Presents Data for LYT-200 Targeting Galectin-9 in Preclinical Leukemia Cancer Models at the 64th American Society of Hematology (ASH) Annual Meeting
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Sonde Health Raises $19.25 Million Series B for Voice-Based Health Monitoring
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Announces New Therapeutic Candidate, LYT-310, an Oral Form of Cannabidiol (CBD) Leveraging PureTech’s Glyph™ Platform
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech to Present at Two Upcoming Investor Conferences
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech to Present at the Jefferies London Healthcare Conference
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech to Present at the Credit Suisse 31st Annual Healthcare Conference
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech to Present at the Morgan Stanley Global Healthcare Conference
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Sonde Health Announces Multi-Year Partnership with Koye Pharmaceuticals
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Akili Announces Phase 3 Study of Digital Treatment in Children with ADHD Begun by Shionogi in Japan
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Akili Announces the Journal Lupus Publishes Investigator-Initiated Study Results Demonstrating Improved Executive Function in Patients with Systemic Lupus Erythematosus Following Use of AKL-T01 Product Candidate
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Akili Announces Public Company Board of Director Nominees
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Initiates Late-Stage Clinical Study of Wholly-Owned Candidate LYT-100 (Deupirfenidone) in IPF and Advances LYT-200 (Anti-Galectin-9 mAb)
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Vedanta Biosciences Unveils State-of-the-Art Manufacturing Facility to Provide Clinical and Commercial Supply of Oral Therapies Based on Defined Bacterial Consortia
From PureTech Health plc
Via Business Wire
Tickers PRTC
Results of Annual General Meeting
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Meets Milestone of Achieving Oral Bioavailability of Allopregnanolone in Healthy Adults Dosed with LYT-300
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Reports Results from Phase 2 Study of LYT-100-COV in Post-Acute “Long” COVID with Respiratory Complications
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Akili Announces Veteran Life Sciences Executive Matt Franklin in Newly Created Role of President and Chief Operating Officer
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Akili Integrates First-of-its-Kind Prescription Video Game Treatment with the Virtual World Through Partnership with Roblox
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Vedanta Biosciences Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech to Present at the UBS Global Healthcare Conference
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Presents Additional Phase 1 Data for LYT-100 at American Thoracic Society 2022
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Announces Share Buyback Program Update
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Announces Share Buyback Program of up to $50 Million
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Gelesis Announces Clinical Data Demonstrating Weight Loss with GS200 in Adults with Prediabetes and Type 2 Diabetes Presented at the European Congress on Obesity 2022
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Gelesis Announces its Proprietary Superabsorbent Hydrogel Induced Beneficial Changes to the Gut Microbiota and Expanded Akkermansia, a Bacterial Species Associated with Gut Health and Weight Loss, in New Study
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Vedanta Biosciences Publishes Phase 1a/1b Results for Lead Program VE303 in Cell Host & Microbe and Highlights Planned Presentations of Phase 2 VE303 Results
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Akili Announces American Journal of Psychiatry Publication of Data Demonstrating its Digital Therapeutic AKL-T03 Improves Cognitive Impairments in Adults w/ Major Depressive Disorder When Combined w/ Antidepressant Medication
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Announces Publication of Research from Collaborators Demonstrating PureTech’s Glyph™ Platform Enhances Oral Absorption of Buprenorphine (a Clinically-Validated Opioid Replacement Therapy)
From PureTech Health plc
Via Business Wire
Tickers PRTC
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Medicine Hat News Twitter Twitter
Medicine Hat News Facebook Facebook
Medicine Hat News Instagram Instagram
Medicine Hat News YouTube YouTube
Medicine Hat News Tumblr Tumblr

About Us

Contact the Medicine Hat News

922 Allowance Ave SE
Medicine Hat, AB T1A 3G7

Office hours: 8:30 a.m.-4:30 p.m. Monday to Friday, closed Saturday Sunday and statutory holidays.

[P] 403.527.1101
[F] 403-527-0737

Print Advertising: 403.528.5659
National Advertising: 403.528.5766
Online Advertising: 403.528.5698
Classifieds: 403.526.7653

© 1996-2024 The Medicine Hat News